Literature DB >> 12604540

Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.

Cristina Seral1, Jean-Michel Michot, Hugues Chanteux, Marie-Paule Mingeot-Leclercq, Paul M Tulkens, Françoise Van Bambeke.   

Abstract

The influence of inhibitors of P-glycoprotein (verapamil [VE], cyclosporine [CY], and GF120918 [GF]) on the cell handling of macrolides (erythromycin [ERY], clarithromycin [CLR], roxithromycin [ROX], azithromycin [AZM], and telithromycin [TEL]) was examined in J774 murine macrophages. The net influx rates of AZM and TEL were increased from 2- to 3.5-fold in the presence of these inhibitors, but their efflux was slowed only marginally. At 3 h, the inhibitors increased the levels of AZM, ERY, and TEL accumulation approximately three- to fourfold (the effect of VE, however, was lower) but did not influence CLR accumulation (the inhibitors had an intermediate behavior on ROX accumulation). The effect was concentration dependent (half-maximal increases in the level of accumulation of AZM were obtained with GF, CY, and VE at 0.5, 5, and 10 micro M, respectively). ATP depletion also caused an approximately threefold increase in the level of accumulation of AZM. Two inhibitors of MRP (probenecid [2.5 mM] and gemfibrozil [0.25 mM]) had no effect. Monensin (a proton ionophore) completely suppressed the accumulation of AZM in control cells as well as in cells incubated in the presence of VE, demonstrating that transmembrane proton gradients are the driving force causing the accumulation of AZM in both cases. Yet, VE did not alter the pH of the lysosomes (approximately 5) or of the cytosol (approximately 7.1). P-glycoprotein was detected by immunostaining at the cell surface as well as in intracellular vacuoles (endosomes and lysosomes). The data suggest that the influx of AZM, ERY, TEL, and ROX is adversely influenced by the activity of P-glycoprotein in J774 macrophages, resulting in suboptimal drug accumulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604540      PMCID: PMC149288          DOI: 10.1128/AAC.47.3.1047-1051.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells.

Authors:  S Ballesta; I García; E J Perea
Journal:  Clin Microbiol Infect       Date:  2001-02       Impact factor: 8.067

Review 2.  Role of transport proteins in drug absorption, distribution and excretion.

Authors:  A Ayrton; P Morgan
Journal:  Xenobiotica       Date:  2001 Aug-Sep       Impact factor: 1.908

3.  Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils.

Authors:  G L Mandell; E Coleman
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers.

Authors:  H Saito; Y Fukasawa; Y Otsubo; K Yamada; H Sezaki; S Yamashita
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 5.  Antibiotic efflux pumps.

Authors:  F Van Bambeke; E Balzi; P M Tulkens
Journal:  Biochem Pharmacol       Date:  2000-08-15       Impact factor: 5.858

Review 6.  Resistance mechanisms associated with altered intracellular distribution of anticancer agents.

Authors:  A K Larsen; A E Escargueil; A Skladanowski
Journal:  Pharmacol Ther       Date:  2000-03       Impact factor: 12.310

7.  Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.

Authors:  L Wang; K Kitaichi; C S Hui; K Takagi; K Takagi; M Sakai; K Yokogawa; K I Miyamoto; T Hasegawa
Journal:  Clin Exp Pharmacol Physiol       Date:  2000-08       Impact factor: 2.557

8.  P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.

Authors:  U I Schwarz; T Gramatté; J Krappweis; R Oertel; W Kirch
Journal:  Int J Clin Pharmacol Ther       Date:  2000-04       Impact factor: 1.366

9.  Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats.

Authors:  S Kiso; S H Cai; K Kitaichi; N Furui; K Takagi; K Takagi; T Nabeshima; T Hasegawa
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

Review 10.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.

Authors:  R Krishna; L D Mayer
Journal:  Eur J Pharm Sci       Date:  2000-10       Impact factor: 4.384

View more
  28 in total

1.  Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.

Authors:  Masami Sugie; Emiko Asakura; Ying Lan Zhao; Shoko Torita; Masayuki Nadai; Kenji Baba; Kiyoyuki Kitaichi; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport.

Authors:  Shoji Yamaguchi; Ying Lan Zhao; Masayuki Nadai; Hideo Yoshizumi; Xiaobo Cen; Shoko Torita; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

Authors:  Alaa H Abuznait; Shawn G Patrick; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

5.  Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  P-glycoprotein-dependent trafficking of nanoparticle-drug conjugates.

Authors:  Erik C Dreaden; Idris O Raji; Lauren A Austin; Shaghayegh Fathi; Sandra C Mwakwari; William H Humphries; Bin Kang; Adegboyega K Oyelere; Mostafa A El-Sayed
Journal:  Small       Date:  2014-02-25       Impact factor: 13.281

7.  Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin.

Authors:  Hugues Chanteux; Isabelle Paternotte; Marie-Paule Mingeot-Leclercq; Robert Brasseur; E Sonveaux; Paul M Tulkens
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

8.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

9.  The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli.

Authors:  Renaud Chollet; Jacqueline Chevalier; André Bryskier; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

Authors:  Françoise Van Bambeke; Stéphane Carryn; Cristina Seral; Hugues Chanteux; Donatienne Tyteca; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.